Background: In a pivotal, randomized, double-blind, placebo-controlled, phase 3 trial of children (6–12y) with ADHD (NCT02520388), treatment with HLD200, an evening-dosed, delayed-release...
Purpose: Evening-dosed HLD200 is a delayed-release and extended-release methylphenidate (DR/ER-MPH) designed to provide treatment effect in the early morning, throughout the day, and into...
Purpose: Evening-dosed HLD200 is a delayed-release and extended-release methylphenidate (DR/ER-MPH) designed to provide treatment effect in the early morning, throughout the day, and into...
Background: Age-adjusted cut-offs for two scales of ADHD-related at-home functional impairment, the Before School Functioning Questionnaire (BSFQ) and the Parent Rating of Evening and Mor...